Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Nivolumab in non-small-cell lung cancer with EGFR mutation.

Annals of oncology : official journal of the European Society for Medical Oncology - 1 Mar 2018

Yoshida H, Kim Y H, Ozasa H, Nagai H, Sakamori Y, Tsuji T, Nomizo T, Yasuda Y, Funazo T, Hirai T

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antineoplastic Agents, Immunological
Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to EGFR gene

Share to Lung Neoplasms

Share to Mutation

Share to Nivolumab

Source

Identifiers

PMID: 29161357
DOI: 10.1093/annonc/mdx745

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Nivolumab in non-small-cell lung cancer with EGFR mutation.PMID 29161357Read ↗

Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLCSemantic proximity Read ↗

Role of epidermal growth factor receptor mutations in predicting sensitivity or resistance to targeted agents in non-small-cell lung cancer.Semantic proximity Read ↗

Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.Semantic proximity Read ↗

Immunotherapy in non-small cell lung cancer harbouring driver mutations.Semantic proximity Read ↗

Selumetinib for the treatment of non-small cell lung cancer.Semantic proximity Read ↗

Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients.Semantic proximity Read ↗

A case treated with nivolumab after small cell lung cancer transformation of mutant EGFR non-small cell lung cancer.Semantic proximity Read ↗

Nivolumab-ipilimumab - exploiting the mutation burden of NSCLCs.Semantic proximity Read ↗

Complete response to nivolumab in Kirsten rat sarcoma virus oncogene KRAS-G12C mutant metastatic lung adenocarcinoma: a case report.Semantic proximity Read ↗

Epidermal growth factor receptor mutations in non-small cell lung cancer: predicting clinical response to kinase inhibitors.Semantic proximity Read ↗

Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722.Semantic proximity Read ↗

Nivolumab after cyclophosphamide and doxorubicin induction chemotherapy in previously treated patients with EGFR or ALK wild type non-squamous cell non-small cell lung cancer with less than 10% of PD-L1 expressionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.